Connection

Co-Authors

This is a "connection" page, showing publications co-authored by SANJEEV VASUDEVAN and SARAH WOODFIELD.
Connection Strength

3.361
  1. HepT1-derived murine models of high-risk hepatoblastoma display vascular invasion, metastasis, and circulating tumor cells. Biol Open. 2022 09 15; 11(9).
    View in: PubMed
    Score: 0.853
  2. An indocyanine green-based liquid biopsy test for circulating tumor cells for pediatric liver cancer. Hepatol Commun. 2024 06 01; 8(6).
    View in: PubMed
    Score: 0.239
  3. Histopathologic and immunophenotypic characterization of patient-derived pediatric malignant hepatocellular tumor xenografts (PDXs). Pathol Res Pract. 2024 Mar; 255:155163.
    View in: PubMed
    Score: 0.235
  4. A novel treatment strategy utilizing panobinostat for high-risk and treatment-refractory hepatoblastoma. J Hepatol. 2024 Apr; 80(4):610-621.
    View in: PubMed
    Score: 0.234
  5. Navigating relapsed hepatoblastoma: Predictive factors and surgical treatment strategy. Cancer Med. 2023 12; 12(23):21270-21278.
    View in: PubMed
    Score: 0.231
  6. An indocyanine green-based liquid biopsy test for circulating tumor cells for pediatric liver cancer. bioRxiv. 2023 Jul 05.
    View in: PubMed
    Score: 0.226
  7. Author Correction: MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma. Sci Rep. 2021 Oct 01; 11(1):19916.
    View in: PubMed
    Score: 0.200
  8. MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma. Sci Rep. 2021 02 03; 11(1):2967.
    View in: PubMed
    Score: 0.191
  9. Animal Modeling of Pediatric Liver Cancer. Cancers (Basel). 2020 Jan 22; 12(2).
    View in: PubMed
    Score: 0.178
  10. Targeting LRH-1 in hepatoblastoma cell lines causes decreased proliferation. Oncol Rep. 2019 Jan; 41(1):143-153.
    View in: PubMed
    Score: 0.163
  11. A Novel Cell Line Based Orthotopic Xenograft Mouse Model That Recapitulates Human Hepatoblastoma. Sci Rep. 2017 12 19; 7(1):17751.
    View in: PubMed
    Score: 0.154
  12. A humanized mouse model for adeno-associated viral gene therapy. Nat Commun. 2024 Mar 04; 15(1):1955.
    View in: PubMed
    Score: 0.059
  13. Quantitative ctDNA Detection in Hepatoblastoma: Implications for Precision Medicine. Cancers (Basel). 2023 Dec 19; 16(1).
    View in: PubMed
    Score: 0.058
  14. Development of Iodinated Indocyanine Green Analogs as a Strategy for Targeted Therapy of Liver Cancer. ACS Med Chem Lett. 2023 Sep 14; 14(9):1208-1215.
    View in: PubMed
    Score: 0.057
  15. Hepatoblastomas with carcinoma features represent a biological spectrum of aggressive neoplasms in children and young adults. J Hepatol. 2022 10; 77(4):1026-1037.
    View in: PubMed
    Score: 0.052
  16. Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signaling. Cancer Lett. 2019 08 10; 457:129-141.
    View in: PubMed
    Score: 0.042
  17. Inhibition of Ubiquitin-Specific Protease 14 Suppresses Cell Proliferation and Synergizes with Chemotherapeutic Agents in Neuroblastoma. Mol Cancer Ther. 2019 06; 18(6):1045-1056.
    View in: PubMed
    Score: 0.042
  18. Small molecule inhibitor regorafenib inhibits RET signaling in neuroblastoma cells and effectively suppresses tumor growth in vivo. Oncotarget. 2017 Nov 28; 8(61):104090-104103.
    View in: PubMed
    Score: 0.038
  19. EWS-FLI1 and RNA helicase A interaction inhibitor YK-4-279 inhibits growth of neuroblastoma. Oncotarget. 2017 Nov 07; 8(55):94780-94792.
    View in: PubMed
    Score: 0.038
  20. Novel multi-targeted ErbB family inhibitor afatinib blocks EGF-induced signaling and induces apoptosis in neuroblastoma. Oncotarget. 2017 Jan 03; 8(1):1555-1568.
    View in: PubMed
    Score: 0.036
  21. Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling. Oncotarget. 2017 Jan 03; 8(1):1469-1480.
    View in: PubMed
    Score: 0.036
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.